dc.contributor.author | Salti, G. I. | en |
dc.contributor.author | Grewal, S. | en |
dc.contributor.author | Mehta, R. R. | en |
dc.contributor.author | Das Gupta, T. K. | en |
dc.contributor.author | Boddie, A. W., Jr. | en |
dc.contributor.author | Constantinou, Andreas I. | en |
dc.creator | Salti, G. I. | en |
dc.creator | Grewal, S. | en |
dc.creator | Mehta, R. R. | en |
dc.creator | Das Gupta, T. K. | en |
dc.creator | Boddie, A. W., Jr. | en |
dc.creator | Constantinou, Andreas I. | en |
dc.date.accessioned | 2019-11-04T12:52:35Z | |
dc.date.available | 2019-11-04T12:52:35Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53346 | |
dc.description.abstract | The present study was undertaken to determine if (a) genistein induces topo II-mediated DNA damage in HT-29 colon cancer cells | en |
dc.description.abstract | and (b) if this damage is required to induce apoptosis. DNA damage was evaluated using the comet assay. Apoptosis was determined by the ethidium bromide/acridine orange staining technique. DNA breakage was noted within 1 h of treatment. Apoptosis was only induced with high concentrations (≥60 μM) of genistein. Marked inhibition of HT-29 cell growth was evident at concentrations ranging from 60 to 150 μM. This was associated with a cell cycle arrest at G2/M. Similar findings were obtained in SW-620 and SW-1116 colon cancer cell lines. Aclarubicin, a topo II antagonist, reduced genistein-induced DNA breaks but did not reduce apoptosis. These data suggest that, in colon cancer cells, topo II serves as the enzymatic target of genistein. Furthermore, topo II-mediated DNA cleavage is not required for the induction of apoptosis. © 2000. | en |
dc.source | European journal of cancer | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034033956&doi=10.1016%2fS0959-8049%2800%2900017-4&partnerID=40&md5=1ef003a14b660ffc41c90a3d523ea945 | |
dc.subject | article | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | human | en |
dc.subject | Humans | en |
dc.subject | breast cancer | en |
dc.subject | controlled study | en |
dc.subject | priority journal | en |
dc.subject | antineoplastic activity | en |
dc.subject | Cell Division | en |
dc.subject | Apoptosis | en |
dc.subject | human cell | en |
dc.subject | DNA topoisomerase (ATP hydrolysing) | en |
dc.subject | Colon cancer | en |
dc.subject | Colonic Neoplasms | en |
dc.subject | cell cycle | en |
dc.subject | cell culture | en |
dc.subject | DNA cleavage | en |
dc.subject | DNA damage | en |
dc.subject | DNA Topoisomerases, Type II | en |
dc.subject | DNA strand breakage | en |
dc.subject | Tumor Cells, Cultured | en |
dc.subject | Dose-Response Relationship, Drug | en |
dc.subject | DNA, Neoplasm | en |
dc.subject | Genistein | en |
dc.subject | aclarubicin | en |
dc.subject | Comet assay | en |
dc.subject | DNA breakage | en |
dc.subject | Antibiotics, Antineoplastic | en |
dc.subject | Growth Inhibitors | en |
dc.title | Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(00)00017-4 | |
dc.description.volume | 36 | |
dc.description.startingpage | 796 | |
dc.description.endingpage | 802 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Cited By :92</p> | en |
dc.source.abbreviation | Eur.J.Cancer | en |
dc.contributor.orcid | Constantinou, Andreas I. [0000-0003-0365-1821] | |
dc.gnosis.orcid | 0000-0003-0365-1821 | |